Cargando…
Ageing is a risk factor in imatinib mesylate cardiotoxicity
AIMS: Chemotherapy-induced heart failure is increasingly recognized as a major clinical challenge. Cardiotoxicity of imatinib mesylate, a highly selective and effective anticancer drug belonging to the new class of tyrosine kinase inhibitors, is being reported in patients, some progressing to conges...
Autores principales: | Maharsy, Wael, Aries, Anne, Mansour, Omar, Komati, Hiba, Nemer, Mona |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4238824/ https://www.ncbi.nlm.nih.gov/pubmed/24504921 http://dx.doi.org/10.1002/ejhf.58 |
Ejemplares similares
-
Delivery as nanoparticles reduces imatinib mesylate-induced cardiotoxicity and improves anticancer activity
por: Marslin, Gregory, et al.
Publicado: (2015) -
Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate
por: Din, Omar S, et al.
Publicado: (2008) -
Periorbital edema secondary to imatinib mesylate
por: McClelland, Collin M, et al.
Publicado: (2010) -
Cutaneous adverse effects of imatinib mesylate
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2015) -
Imatinib Mesylate-Induced Hyperpigmentation of the Nose and Palate
por: Song, Hyo Sang, et al.
Publicado: (2014)